Cost of de novo acute myeloid leukemia induction therapy in adults: Analysis of EORTC-GIMEMA AML10 and FLANG regimens

Journal of Experimental and Clinical Cancer Research

Volumn 20, Issue 2, 2001, Pages 165-173

  Clavio, M ^a   Quintino, S ^a   Masoudi, B ^a   Carrara, S ^a   Cerri, R ^a   Pierri, I ^a   Canepa, L ^a   Miglino, M ^a   Muner, P ^a   Damasio, E ^a   Gobbi, M ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

AML induction therapy; AML 10; Cost; FLANG; Fludarabine

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COSTS AND COST ANALYSIS; CYTARABINE; DRUG COSTS; DRUG SYNERGISM; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MITOXANTRONE; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIDARABINE;

EID: 0034934467     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML)
2. Low dose cytarabine versus intensive chemotherapy in the treatment of acute non lymphocytic leukemia in the elderly
3. Cost analysis
4. Cost analysis of leukemia treatment
5. Programme de medicalisation des systemes d' information: Validitè du calcul des couts directs pour le traitement initial de la leucemie aigue myeloblastique
6. Treating acute leukemia: A venture into economic uncertainty. Report of a method for estimating the cost of treating patients with acute myelocytic leukemia
7. Acute myeloblastic leukemia: A model for assessing value for money for new treatment programmes
8. Cost of complete remission induction in acute myeloblastic leukemia: Evaluation of the cost effectiveness of a new drug
9. Costs over time in conventional treatment of acute myeloid leukemia. A study exploring changes in treatment strategies over two decades
10. Costs of bone marrow transplants in acute myeloid leukemia
11. Cost effectiveness of bone marrow transplantation in acute myeloid leukemia
12. Sequential administration of Fludarabine, Ara-C and mitoxantrone enhances topoisomerase II-DNA complexes and has efficacy in acute leukemia. Report of ASH 92
13. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia
14. FLAG (fludarabine+high dose cytarabine+G-CSF): An effective and tolerable protocol for the treatment of "poor risk" acute myeloid leukemias
15. FLAG (Fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia
16. FLAG is a useful regimen for poor prognosis adult myeloid leukemias and myelodisplastic syndromes
17. Fludarabine, cytarabine and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia
18. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor risk myelodysplastic syndromes and acute myeloid leukemia
19. Arabinoside + idarubicin ± all-trans retinoic acid ± granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
20. Fludarabine inhibits DNA replication: A rationale for its use in the treatment of acute leukemias
21. The cost effectiveness of idarubicin / cytosine arabinoside versus daunorubicin / cytosine arabinoside in the treatment of adults with acute myeloid leukemia
22. Morbidity and costs of remission induction therapy with all-trans retinoic acid compared with standard chemotherapy in acute promyelocytic leukemia
23. A double blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group Study (9031)
24. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML cooperative study group
25. A randomized, double blind, placebo controlled, phase III study of filgrastim in remission induction and consolidation therapy for adult de novo acute myeloid leukemia
26. Granulocyte-macrophage colony-stimulating factor in elderly patients with primary acute myelogenous leukemia
27. On the value of intensive remission induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: A randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group
28. A randomized placebo-controlled phase III study of granulocyte-macrophage CSF in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Ontology Group
29. Cost-effectiveness and quality of life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia
30. Planned progressive antimicrobial therapy in neutropenic patients
31. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukemia
32. 9 / 1 trigger: A prospective comparative trial in 105 patients with acute myeloid leukemia
33. Use of G-CSF before, during and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: Comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor
34. Lack of benefit of G-CSF on complete remission and possible increased relapse risk in AML: An MRC study of 800 patients